Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Rebecca Kristeleit
ENGOT-ov-6/TRINOVA-2: Randomised, Double-Blind, Phase 3 Study of Pegylated Liposomal Doxorubicin Plus Trebananib or Placebo in Women With Recurrent Partially Platinum-Sensitive or Resistant Ovarian Cancer
European Journal of Cancer
Cancer Research
Oncology
Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-Label Studies
Clinical Therapeutics
Pharmacology
Related publications
Randomized Phase II Study of the PDGFRα Antibody Olaratumab Plus Liposomal Doxorubicin Versus Liposomal Doxorubicin Alone in Patients With Platinum-Refractory or Platinum-Resistant Advanced Ovarian Cancer
BMC Cancer
Cancer Research
Oncology
Genetics
Olaparib Tablets as Maintenance Therapy in Patients With Platinum-Sensitive, Relapsed Ovarian Cancer and a BRCA1/2 Mutation (SOLO2/ENGOT-Ov21): A Double-Blind, Randomised, Placebo-Controlled, Phase 3 Trial
The Lancet Oncology
Oncology
Non‑pegylated Liposomal Doxorubicin for Patients With Recurrent Ovarian Cancer: A Multicentric Phase II Trial
Oncology Letters
Cancer Research
Oncology
Docetaxel and Dasatinib or Placebo in Men With Metastatic Castration-Resistant Prostate Cancer (READY): A Randomised, Double-Blind Phase 3 Trial
The Lancet Oncology
Oncology
LBA40_PRARIEL3: A Phase 3, Randomised, Double-Blind Study of Rucaparib vs Placebo Following Response to Platinum-Based Chemotherapy for Recurrent Ovarian Carcinoma (OC)
Annals of Oncology
Medicine
Oncology
Hematology
Veliparib and Topotecan for Patients With Platinum-Resistant or Partially Platinum-Sensitive Relapse of Epithelial Ovarian Cancer With BRCA Negative or Unknown BRCA Status
Cancer Treatment and Research Communications
Cancer Research
Oncology
Emerging Pharmacotherapies in Ovarian Cancer: Focus on Pegylated Liposomal Doxorubicin
Clinical Medicine Reviews in Women's Health
Phase 1–2 Study of Docetaxel Plus Aflibercept in Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
The Lancet Oncology
Oncology
Prm212 - Patient Experience With Platinum-Resistant or Platinum-Refractory Ovarian Cancer
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
